GC Genome Registers Patent for AI-Based Multi-Cancer Early Detection Technology in Japan

Proven Core Technology for Multi-Cancer Early Screening
Accelerating Entry into the Global Precision Medicine Market

GC Genome, a company specializing in liquid biopsy and clinical genomics analysis, announced on June 18 that its core technology "FEMS (Fragment End Motif by Size)" for its AI-based multi-cancer early screening test "ai-CANCERCH" has been granted an original patent in Japan.

ai-CANCERCH is an innovative screening service that enables the early detection of more than six types of cancer?including lung, liver, colorectal, pancreatic and biliary tract, esophageal, and ovarian cancer?with a single blood draw.

The patented "FEMS" technology can sensitively detect even the faintest cancer signals in blood. Using a proprietary AI algorithm, it analyzes two types of information: the "fragment size of cell-free DNA (cfDNA)" and the "end motif sequence pattern." This allows for the precise identification of trace cancer cell-derived signals that are difficult to detect with conventional technologies. This technology was published this year in the international cancer journal "Cancer Research (IF 12.5)," where it was recognized for its potential to dramatically improve early cancer detection rates.

GC Genome also completed patent registration in Japan this April for its AI-based non-invasive minimal residual disease detection technology (G-MRD). This technology can be used for recurrence monitoring, assessment of treatment efficacy, and prognosis prediction in cancer patients. Alongside multi-cancer early detection technology, it further enhances the value of precision medicine applications.

ai-CANCERCH was officially launched in the Japanese market in April. In collaboration with GC Lymphotec, a GC Group affiliate based in Japan, the company is expanding its hospital network and partnerships.

The company stated that it is accelerating the establishment of a precision diagnostics platform that covers the entire cancer care cycle in the Japanese market?from screening to post-treatment recurrence monitoring?and is further strengthening its position in the global precision medicine market.

Ki Changseok, CEO of GC Genome, said, "The patent registration of FEMS technology in Japan signifies international recognition of our original multi-cancer early detection technology," adding, "We will further accelerate R&D and global market expansion to continue technology-driven growth in the field of precision medicine."

Meanwhile, multi-cancer early detection technology was selected earlier this year as one of the "Top 10 Promising Bio Technologies of the Future" by the Ministry of Science and ICT and the Korea Research Institute of Bioscience and Biotechnology, drawing attention as a key technology in the advanced bio sector.